Effect of Intratrigonal Botulinum Toxin in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Long-Term, Single-Center Study in Real-Life Conditions
Author:
Abreu-Mendes PedroORCID, Ferrão-Mendes AntónioORCID, Botelho Francisco, Cruz FranciscoORCID, Pinto Rui
Abstract
The high percentage of treatment failures seen in patients with bladder pain syndrome/interstitial cystitis (BPS/IC) managed conservatively frequently demands invasive treatment options. We aimed to evaluate the long-term efficacy and adverse events of intratrigonal botulinum toxin injection in such circumstances, as well as to determine possible predictors of response to toxin treatment. A retrospective cohort study included 47 female BPS/IC patients treated with onabotulinum toxin A (OnabotA) in a tertiary hospital between the years 2009 and 2022. All patients received 100 U of OnabotA in ten injections limited to the trigonal area. Patients were divided into three groups based on their treatment response as responders, non-responders and lost to follow-up due to non-medical reasons. The clinical and surgical records of the individuals were retrieved, including the 10-point visual analogue scale (VAS), the number of treatments, the time between injections, and the age at the first injection. A total of 25 patients (>50% of the cohort) were long-term responders, but none of the evaluated parameters was a predictor for this circumstance: age, pain intensity, or duration of improvement following the injection. The time between injections was stable (around 1 year). No severe adverse events were registered. The intratrigonal injection of botulinum toxin in patients with BPS/IC was an effective and safe long-term treatment for patients’ refractory to conservative forms of treatment. Age, basal pain intensity, and time to injection request did not predict long-term response to OnaBotA.
Subject
Health, Toxicology and Mutagenesis,Toxicology
Reference29 articles.
1. Diagnostic Criteria, Classification, and Nomenclature for Painful Bladder Syndrome/Interstitial Cystitis: An ESSIC Proposal;Eur. Urol.,2008 2. Engeler, D., Baranowski, A.P., Berghmans, B., Borovicka, J., Cottrell, A.M., Dinis-Oliveira, P., Elneil, S., Hughes, J., Messelink, J.M., and Pinto, R.A. (2022, November 04). EAU guidelines on chronic pelvic pain 2022. Eur. Urol.2022. Available online: https://uroweb.org/guidelines/chronic-pelvic-pain. 3. Guideline of guidelines: Bladder pain syndrome;BJU Int.,2018 4. Engeler, D., Baranowski, A.P., Berghmans, B., Borovicka, J., Cottrell, A.M., Dinis-Oliveira, P., Elneil, S., Hughes, J., Messelink, J.M., and Pinto, R.A. (2021). EAU Guidelines, Edn. Presented at the EAU Annual Congress Milan 2021, Elsevier. 5. Intratrigonal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial;J. Urol.,2018
|
|